Pfizer opted to discontinue the product for "several reasons," including limited interest from patients and physicians in gene therapies for hemophilia.
With Mayne Pharma subject to a $670 million takeover offer, investor attention turns to who might be acquired next.
Pfizer has partnered with Summit Therapeutics to evaluate ivonescimab, a PD-1/VEGF bispecific antibody, in combination with ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Ltd. (BABA), ...
Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
The weight-loss drug market is heating up, with Swiss company Roche making a bold move by acquiring Carmot Therapeutics for up to $3.1 billion in 2023. This investment is aimed at accelerating its ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Pfizer Inc. (NYSE:PFE – Get Free Report) was the target of some unusual options trading activity on Friday. Stock traders ...
One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...